Skip to main content

Plexera Signs Early-Access Customer for ProteomicProcessor


NEW YORK (GenomeWeb News) - Plexera said today it has inked an agreement with an undisclosed early-access customer for its antibody discovery system, which it expects to launch in May 2008. 
 
Plexera said the partner, a therapeutic antibody company, intends to purchase one of the ProteomicProcessor Systems when the platform is commercially available.
 
The company said the system combines surface plasmon resonance technology with microarray multiplex capabilities to detect and monitor biomolecular binding kinetics for as many as 5,000 antigen-antibody interactions in one run.
 
Plexera, a subsidiary of Lumera, said its platform combines antibody screening and analysis of binding properties, concentration, and kinetics into a single process that can help speed up drug discovery research.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.